TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06204588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group: SFA only
Description: Single flap approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group 1: VCMX + Low level LASER therapy + Single flap approach
Description: using collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group 2: Low level LASER therapy + Single flap approach
Description: Laser therapy in horizontal bone loss defects by single flap approach (SFA+LLLT).
Study: NCT04826783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lasers
Description: The laser tip was applied as vertical and horizontal scan along the subgingival implant . The procedure was carried out on day zero, seven and 14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lasers
Description: The laser tip was applied as vertical and horizontal scan along the subgingival implant . The procedure was carried out on day zero, seven and 14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lasers
Description: The laser tip was applied as vertical and horizontal scan along the subgingival implant . The procedure was carried out on day zero, seven and 14.
Study: NCT04949503

Intervention type: DRUG
Intervention: nimotuzumab
Description: Patients in the study group were received nimotuzumab on the basis of chemoradiotherapy (control group).
Study: NCT05106335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab + famitinib
Description: camrelizumab for intravenous injection; famitinib malate capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famitinib
Description: famitinib malate capsules for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel for intravenous injection
Study: NCT05906108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-initiated learning
Description: A WeChat Subscription will be created for delivering the intervention. The educational materials involving introduction to internet addiction, the impact of internet addiction and strategies in coping with IA will be posted to the account at the beginning of the intervention. The materials will be prepared in different format including text and video followed by 3 to 5 multiple choice questions (MCQs), and one post for one topic. Relevant materials can be found by typing the keywords in the account or searching under the content list. Participants will be required to follow the account to study the materials at their own pace and complete the MCQs. There will be no limited access to the materials and attempts for MCQs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized and interactive behavioural support
Description: The intervention group will receive 3-month personalized and interactive behavioural support via WeChat, which including regular messages and real-time conversation. The regular messages will cover the generic information about abstinence support, health warnings, benefits of reducing internet time, knowledge reinforcement, goal setting, encouragement and reminders for self-initiated online learning. The messages will be personalised according to baseline demographic characteristics and internet addiction level, and continually adapted to any change in internet behaviours change reported by subjects during the conversations. A total of 19 messages with a tapering schedule. Personalized real-time conversation via WeChat will be available based on participants' demand.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health information
Description: Participants in control group will receive WeChat messages on general health information (similar frequency as the intervention group) and reminders on follow-up surveys via WeChat. Various topics will be involved in the general health information such as healthy diet, sleep management, exercise and mood management.
Study: NCT05009680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered orally twice a day
Study: NCT06138990

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacoscopy
Description: Pharmacoscopy (PCY) is an image-based ex vivo drug testing platform developed by the Snijder lab at the ETH Zurich. PCY measures in the drug response of patient cells from small biopsies using automated microscopy and single-cell image analysis. PCY prioritizes treatments based on their specific efficacy against AML cells, while minimizing toxicity to healthy (non-malignant) cells in the patient biopsy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clinical standard-of-care (physician's choice)
Description: Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
Study: NCT05398861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Combined with Bevacizumab
Description: Utidelone： 30 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle Bevacizumab：10mg/kg (IV), on day 1 of each 21 days.
Study: NCT04679662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (PLAR Implant and Delivery System)
Description: The PLAR Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
Study: NCT06490445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Cannabis
Description: Syqe cartridge containing medical cannabis (Bedrocan®) administered using Fixed-dose Syqe Inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Cannabis
Description: Syqe cartridge containing medical cannabis (Bedrocan®) administered using Fixed-dose Syqe Inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Cannabis
Description: Syqe cartridge containing medical cannabis (Bedrocan®) administered using Fixed-dose Syqe Inhaler.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered using Fixed-dose Syqe Inhaler.
Study: NCT04763564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector
Description: Treatment will be initiated at 0.6 mg per day for one week. The patient will be instructed to increase the dose to 1.2/day and 1.8 mg /day in week 2 and in week 3, respectively. From week 3 after the start of the drug until week 6 the patient will apply 1.8 mg/day liraglutide. In case of intolerance (e.g. occurrence of refractory nausea) at a higher dose (e.g. 1.8 mg daily, the highest dose in this trial) liraglutide can be reduced to the previous level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector
Description: Treatment will be initiated at 0.6 mg per day for one week. The patient will be instructed to increase the dose to 1.2/day and 1.8 mg /day in week 2 and in week 3, respectively. From week 3 after the start of the drug until week 6 the patient will apply 1.8 mg/day liraglutide. In case of intolerance (e.g. occurrence of refractory nausea) at a higher dose (e.g. 1.8 mg daily, the highest dose in this trial) liraglutide can be reduced to the previous level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Pen Injector
Description: Matching placebo pens used to administer normal saline in the same fashion as for liraglutide
Study: NCT06396598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Review education materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Participate use the electronic symptom monitoring program to log symptoms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Watch a video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05698758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrometropine and 0.9% sodium chloride solution
Description: Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrometropine and 0.9% sodium chloride solution
Description: Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery
Study: NCT05806060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine
Description: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel, with maintenance of capecitabine
Description: Nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1
Description: TPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGFR and TPC
Description: VEGFR bevacizumab and TPC
Study: NCT05736978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/m2 d1-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: d1 100mg, d2 200mg, d3-28 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: if MRD positive in C1D14, selinexor 60mg D15, D22
Study: NCT05433636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Scan
Description: Patients will listen to a 5-minute, audio-recorded body scan practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Breathing
Description: Patients will listen to a 5-minute, audio-recorded mindful breathing practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness of Discomfort
Description: Patients will listen to a 5-minute, audio-recorded mindfulness of discomfort practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Savoring
Description: Patients will listen to a 5-minute, audio-recorded mindful savoring practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrative Health Recording
Description: Patients will listen to a 5-minute, audio-recorded description of integrative health.
Study: NCT05602207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib
Description: 100 mg Abrocitinib once daily (QD) for 12 weeks
Study: NCT04763564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Pen Injector
Description: Matching placebo pens used to administer normal saline in the same fashion as for liraglutide
Study: NCT04859621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU
Description: Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 IU
Description: Oral administration, 1 tablet of each per time, qd, oral administration with the first meal, continuous use for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard antibiotic therapy
Description: standard antibiotic therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard antibiotic therapy
Description: standard antibiotic therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard antibiotic therapy
Description: standard antibiotic therapy
Study: NCT05693207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG
Description: wearables EMG

Intervention type: DEVICE
Group type: OTHER
Intervention: EMG
Description: wearables EMG
Study: NCT05888623

Intervention type: DEVICE
Intervention: Computer Assisted Detection
Description: Computer-aided polyp detection system that utilizes artificial intelligence (AI) during colonoscopy
Study: NCT05640336

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Debridement, Antibiotics and Implant Retention
Description: Surgical debridement and wash out of infected joint. The polyethylene (plastic) insert, which acts as the articulating surface (modular component) of the prosthesis, will be removed and the exposed surfaces scrubbed, sterilized, and soaked. A new modular component will be placed with additional irrigation and antiseptic soak. Tissue cultures will be sent to the lab for further evaluation and antibiotic guidance. After the operation subjects will continue six weeks of IV antibiotics followed by oral antibiotic suppression for the life of the implant or at least two years after operation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Planned Double Debridement, Antibiotics and Implant Retention
Description: Surgical debridement and wash out of infected joint with an additional irrigation and debridement scheduled for approximately 5 days after the initial DAIR. During the first washout, antibiotic cement beads will be placed in the joint and these will remain in the interim until they are removed during the second washout. During the second DAIR, the antibiotic beads are removed, and the modular components are once again removed and replaced with new components. Exposed surfaces are again irrigated and debrided following a standardized protocol. A six-week course of IV antibiotics will follow the DAIR with additional oral antibiotics for the life of the component (standard of care) or at least a minimum of two years.
Study: NCT05323331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit Training Exercise Program
Description: The participants allocated to this group will perform Circuit Training Exercise Program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training Exercise Program
Description: The participants allocated to this group will perform Circuit Training Exercise Program
Study: NCT06126068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of magnesium sulfate to prevent and stop fits in pre-eclampsia and Eclampsia
Description: Loading dose magnesium sulfate versus the Pritchard regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of magnesium sulfate to prevent and stop fits in pre-eclampsia and Eclampsia
Description: Loading dose magnesium sulfate versus the Pritchard regimen
Study: NCT06486961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeatMove Application
Description: The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BeatMove Application without synchronized music
Description: The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BeatMove Application without music
Description: The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
Study: NCT05744323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional training
Description: Physical and motor function training for children,may use BOSU balls, medicine balls, balance mats, fitness steps, and other training equipment to improve gradually
Study: NCT06299917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WORK-ON
Description: The intervention includes three parts: 1) a coordinating occupational therapist, 2) four group sessions and 3) Individual consultations based on the agreed upon goals.
Study: NCT05900557

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECoG monitoring
Description: Brief (1-5 days) of post operative ECoG monitoring to detect spreading depolarization.
Study: NCT05989113

Intervention type: OTHER
Intervention: Administration of the IPAQ-SF questionnaire
Description: Administration of the IPAQ-SF questionnaire at the patient's consultation and upon return home
Study: NCT04809883

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoflip measurement of gastric and pyloric function
Description: Endoflip device to measure gastric and pyloric functions
Study: NCT05298319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.
Study: NCT05727072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3848575
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3848575
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT05492253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant fruit
Description: Infants will be fed prune puree

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant vegetable
Description: Infants will be fed carrot puree

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant meat
Description: Infants will be fed beef puree

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant grain
Description: Infants will be fed oatmeal cereal
Study: NCT05810194

Intervention type: DEVICE
Intervention: StrataXRT
Description: StrataXRT® is a TGA-approved silicone-based topical preparation. StrataXRT is a self-drying, non-sticky, transparent, silicone gel formulation and when used as directed, dries to form an inert, thin, flexible wound dressing with a protective layer that is gas permeable and waterproof. It is the only self-drying topical silicone gel indicated for the use on radiation dermatitis, which hydrates and protects compromised skin areas and open wounds from chemical and microbial invasion. StrataXRT helps create an optimal wound healing environment which leads to faster re-epithelialization and a reduced inflammatory response. The product can be applied to fresh incisions and excisions, open wounds and compromised skin surfaces.
Study: NCT05291065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasted exercise
Description: Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High protein breakfast exercise
Description: Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High carbohydrate breakfast exercise
Description: Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
Study: NCT05810194

Intervention type: DRUG
Intervention: Calendula
Description: Calendula creams are over-the-counter (OTC) skin care ointments that are non-greasy, non-sticky, and quickly absorbed by the skin. Calendula is a topical agent derived from a plant of the marigold family Calendula Officinalis and is used in cuts, scrapes, chafing and minor burns. Containing numerous polyphenolic antioxidants, calendula has been studied in both the laboratory and clinical setting for the use in treating and preventing radiation induced skin toxicity.